Zymeworks Cash Flow Statement
NASDAQ: ZYMEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zymeworks free cash flow
In fiscal 2025, Zymeworks generated -$33.0 million of operating cash flow and spent $1.5 million on capital expenditures. That left free cash flow of -$34.5 million, a free-cash-flow margin of -32.6% of revenue. Zymeworks returned $41.7 million to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
Zymeworks cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -81.13M | -122.69M | -118.67M | 124.34M | -211.84M | -180.55M |
| Net Income growth (YoY) | — | — | -195.44% | — | — | — |
| Depreciation & Amortization | 3.67M | 4.19M | 7.46M | 6.22M | 3.74M | 3.35M |
| Stock-Based Compensation | 28.03M | 17.79M | 8.10M | 4.01M | 10.76M | 29.12M |
| Change in Working Capital | 10.89M | -20.97M | -22.87M | 6.91M | 419.00K | -9.01M |
| Operating Cash Flow | -33.01M | -110.06M | -118.32M | 144.11M | -192.45M | -151.40M |
| Capital Expenditures | -1.52M | -1.99M | -2.47M | -8.15M | -12.40M | -4.31M |
| Investing Cash Flow | 26.66M | 38.76M | -207.25M | -53.85M | 144.60M | -43.44M |
| Share Repurchases | -41.70M | -30.05M | 0 | 0 | — | — |
| Financing Cash Flow | -18.56M | -20.44M | 81.87M | 108.58M | 8.01M | 308.98M |
| Net Change in Cash | -24.95M | -91.45M | -243.35M | 199.04M | -40.17M | 113.58M |
| Free Cash Flow | -34.53M | -112.05M | -120.80M | 135.96M | -204.85M | -155.71M |
This table shows 6 annual periods of Zymeworks's cash flow statement, from FY 2025 back to FY 2020, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ZYME's reporting calendar. What is a cash flow statement?